Clinical trials suggest GLP‐1 receptor agonists (RAs) and dual glucagon‐like peptide‐1 (GLP‐1)/glucose‐dependent insulinotropic polypeptide (GIP) RAs improve metabolic dysfunction associated with steatohepatitis (MASH) in patients with metabolic dysfunction‐associated steatotic liver disease (MASLD). Here, GIP is linked to metabolic process.